Blood pressure is a major cardiovascular disease risk factor. To date, few variants associated with interindividual blood pressure variation have been identified and replicated. Here we report results of a genome-wide association study of systolic (SBP) and diastolic (DBP) blood pressure and hypertension in the CHARGE Consortium (n ¼ 29,136), identifying 13 SNPs for SBP, 20 for DBP and 10 for hypertension at P o 4 Â 10 À7 . The top ten loci for SBP and DBP were incorporated into a risk score; mean BP and prevalence of hypertension increased in relation to the number of risk alleles carried. When ten CHARGE SNPs for each trait were included in a joint meta-analysis with the Global BPgen Consortium (n ¼ 34,433), four CHARGE loci attained genome-wide significance (P o 5 Â 10 À8 ) for SBP (ATP2B1, CYP17A1, PLEKHA7, SH2B3), six for DBP (ATP2B1, CACNB2, CSK-ULK3, SH2B3, TBX3-TBX5, ULK4) and one for hypertension (ATP2B1). Identifying genes associated with blood pressure advances our understanding of blood pressure regulation and highlights potential drug targets for the prevention or treatment of hypertension.
regulatory genes 9 , and common variants in two renal sodium regulatory genes have been found to be associated with blood pressure in the general population 10 . The vast majority of the genetic contribution to variation in blood pressure, however, remains unexplained.
Large-scale genome-wide association studies (GWAS), in which hundreds of thousands of common genetic variants are genotyped and analyzed for disease association, have shown great success in identifying genes associated with common diseases and traits 11, 12 . Six GWAS published to date, however, have not identified loci associated with blood pressure or hypertension at P o 5 Â 10 À8 , raising concerns about the utility of this approach for these traits [13] [14] [15] [16] [17] [18] .
If blood pressure variation in the general population is due to multiple variants with small effects, very large study samples are needed to identify them. We established the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) Consortium 19 to identify common genetic variation associated with complex traits. The CHARGE Consortium consists of 29,136 participants of European descent who had undergone standardized blood pressure measurements in six population-based cohort studies: the Age, Gene/Environment Susceptibility Reykjavik Study (AGES), Atherosclerosis Risk in Communities (ARIC) Study, Cardiovascular Health Study (CHS), Framingham Heart Study (FHS), Rotterdam Study (RS) and the Rotterdam Extension Study (RES). We report the top findings of our GWAS of systolic blood pressure, diastolic blood pressure and hypertension, provide replication results for our most promising loci in the Global BPgen Consortium 20 , another GWAS consortium of similar size, and report combined meta-analysis findings of the two consortia for the most promising loci found in CHARGE.
RESULTS

Study samples
The total sample size for this analysis was 29,136 (AGES, n ¼ 3,219; ARIC, n ¼ 8,047; CHS, n ¼ 3,277; FHS, n ¼ 8,096; RS n ¼ 4,737; RES, n ¼ 1760). Characteristics of the study sample are presented in Supplementary Table 1 online. The mean age of the study participants at the initial examination varied from 38 years (FHS) to 72 years (CHS). The mean observed (and treatment corrected) SBP across the six cohorts ranged from 118 (120) mm Hg (ARIC) to 143 (145) mm Hg (RES); the mean DBP ranged from 72 (73) mm Hg (ARIC) to 83 (84) mm Hg (AGES). The proportion of participants taking antihypertensive medication ranged from 5% (FHS) to 38% (CHS), and the proportion with hypertension ranged from 17% (FHS) to 60% (RES).
Meta-analysis of CHARGE cohort results
Within-cohort analyses were combined by meta-analysis and the results for all SNPs with P value o1 Â 10 À6 are presented in Table 1 for SBP, Table 2 for DBP and Table 3 for hypertension; within each of these tables the results for the other two blood pressure phenotypes are also provided. Supplementary Table 2 online provides summary data for the top SNPs for each phenotype for each of the six cohorts. Quantile-quantile and Àlog 10 (P) genome-wide association plots are presented in Supplementary Figure 1 online for SBP, DBP and hypertension. The quantile-quantile plots show departure from the line of identity at approximately 1 Â 10 À3 for systolic and diastolic blood pressure. The number of SNPs with P values o1 Â 10 À3 was 3,433 for systolic and 3,558 for diastolic blood pressure versus 2,540 expected. The proportion of SNPs with P o 1 Â 10 À3 that are intragenic was 47% for systolic and diastolic blood pressure versus an average of 37% for all imputed SNPs. For systolic blood pressure the meta-analysis identified 13 SNPs with P o 4 Â 10 À7 (stage 1 threshold). The strongest signal for systolic pressure was for rs2681492 (P ¼ 3.0 Â 10 À11 ) in ATP2B1 on chromosome 12q21-23. A low minor allele frequency variant in C18orf1 (rs8096897; P ¼ 3.2 Â 10 À8 ) showed evidence of association with SBP as did CASZ1 (rs880315; P ¼ 2.1 Â 10 À7 ). A signal was identified on chromosome 12q24 for SH2B3 (rs3184504; P ¼ 5.7 Â 10 À7 ) and for nearby ATXN2 ) and a locus on chromosome 2q31-33 adjacent to PMS1 and MSTN (rs7571613, P ¼ 7.2 Â 10 À7 ) showed suggestive evidence of association. Of note, many of the top SBPassociated SNPs were also associated with other blood pressure phenotypes ( Table 1) . The top allelic associations were generally consistent in size and direction across the six individual cohorts (Supplementary Table 2 ). For DBP ( Table 2) there were 20 SNPs with P o 4 Â 10 À7 . Significant association signals were detected in a large 1-Mb block of linkage disequilibrium on chromosome 12q24 that includes SH2B3 (rs3184504, P ¼ 1.7 Â 10 À8 ), ATXN2 (rs653178, P ¼ 2.0 Â 10 À8 ; r 2 ¼ 1.0 with rs3184504), and TRAFD1 (rs17630235, P ¼ 1.0 Â 10 À7 ; r 2 ¼ 0.66 with rs3184504). This block encompasses CUTL2, FAM109A, SH2B3, ATXN2, BRAP, ACAD10, ALDH2, MAPKAPK5, TMEM116, ERP29, C12orf30, TRAFD1, C12orf51, RPL6 and PTPN11 (Supplementary Fig. 2 online) . In addition, ATP2B1 (chromosome 12q21, rs2681472, P ¼ 3.7 Â 10 À8 ), TBX3-TBX5 (chromosome 12q24, rs2384550, P ¼ 1.3 Â 10 À7 ) and PLEKHA7 (chromosome 11p15, rs11024074, P ¼ 2.8 Â 10 À7 ) showed association with DBP. Suggestive evidence of association was found for loci in or adjacent to ULK4 (chromosome 3p22.1), CSK-ULK3 (chromosome 15q24) and CACNB2 (chromosome 10p12). Multiple DBP-associated SNPs were also associated with other blood pressure phenotypes ( Table 2) . The top allelic associations were generally consistent in size and direction across studies (Supplementary Table 2) .
For the dichotomous trait of hypertension (Table 3) , one significant association was detected for ATP2B1 (rs2681472, P ¼ 1.7 Â 10 À8 ), with an odds ratio for hypertension of 1.17 per risk allele. Suggestive evidence of association was detected for ITGA9 (chromosome 3p22.2, rs7640747, P ¼ 4.8 Â 10 À7 ) and CACNB2 (rs11014166, P ¼ 7.8 Â 10 À7 ).
Independent replication and meta-analysis of top CHARGE SNPs Thirty SNPs representing the top ten CHARGE Consortium loci for SBP, DBP and hypertension were exchanged for lookup within the Global BPgen Consortium GWAS results. One SNP for SBP, four for DBP and one for hypertension that attained stage 1 P o 4 Â 10 À7 in CHARGE were assessed for evidence of independent replication in Global BPgen ( Table 4) . Five of these six associations fulfilled criteria for external replication in Global BPgen of P o 0.008 (0.05/6, onetailed test). The replicated loci included ATP2B1 (for SBP, DBP and hypertension), SH2B3 (DBP) and TBX3-TBX5 (DBP). PLEKHA7 did not replicate for DBP (rs11024074, P ¼ 0.03 in Global BPgen); however, another SNP in PLEKHA7 was genome-wide significant (at P o 5 Â 10 À8 , stage 2) for SBP (rs381815) in the joint metaanalysis of CHARGE and Global BPgen. Of note, for 29 of 30 CHARGE SNPs that were exchanged, the directional association (sign of beta) was identical in both consortia. Table 4 provides results of joint meta-analysis of CHARGE and Global BPgen for the top ten CHARGE SNPs for SBP, DBP and hypertension. Four genome-wide significant (stage 2 P o 5 Â 10 À8 ) associations emerged for SBP (CYP17A1, PLEKHA7, ATP2B1 and SH2B3), six for DBP (ULK4, CACNB2, ATP2B1, SH2B3, TBX3-TBX5 and a locus adjacent to CSK-ULK3) and one for hypertension (ATP2B1). Three additional associations attained P o 4 Â 10 À7 (MDS1 for SBP; CACNB2 and a region near EDN3 for hypertension). Plots of association results across each of the genome-wide significant loci are presented in Figures 1 and 2 using the SNAP tool 21 Blood pressure risk score Weighted risk scores, incorporating the top ten CHARGE loci for SBP and DBP, were applied to the study results to examine the influence of risk alleles in aggregate on deviation from mean blood pressure levels and odds ratios for hypertension. Figure 3 shows a continuous and graded relation of risk score on blood pressure levels and odds ratios for hypertension. Inverse-variance weighted regression estimates of slope (beta) and its standard error (s.e.) were obtained across risk score groups for deviation from mean blood pressure and odds ratios for hypertension. To summarize these findings, two-tailed P values (from Z ¼ beta/s.e.(beta)) were obtained from testing the null hypothesis of a zero slope across risk score groups. The P values across risk score groups were as follows: 1.8 Â 10 À27 (SBP versus SBP risk score), 1.7 Â 10 À56 (DBP versus DBP risk score), 1.4 Â 10 À17 (hypertension versus SBP risk score) and 8.4 Â 10 À10 (hypertension versus DBP risk score).
Putative functional variation
A search for nonsynonymous SNPs among our blood pressure association results identified five such variants, including rs3184504 in SH2B3 (stage 2 P value for DBP ¼ 2.6 Â 10 À14 ), rs267561 in ITGA9 (stage 1 P value for hypertension 2.6 Â 10 À6 ) and three linked nonsynonymous SNPs in ULK4 (rs2272007, rs3774372 and rs1716975; pairwise r 2 ¼ 0.82-1.0; lowest stage 1 P value ¼ 1.5 Â 10 À6 for DBP). To further identify putative functional associations within our GWAS results, we culled from the 2.5 million HapMap SNPs in our analysis those that were previously reported from GWAS to be associated with altered gene expression in liver 22 (n ¼ 3,322) or lymphoblastoid cell lines 23 (n ¼ 10,823). These expression-associated SNPs (eSNPs or eQTLs) were then interrogated for association with blood pressure phenotypes within our GWAS results ( Table 5) . Of note, three of our genome-wide significant loci were captured through the analysis eSNPs, including rs739496 in SH2B3, which is associated with altered expression of nearby HSS00340376 in liver; rs6495126 near CSK-ULK3, which is associated with altered expression of ULK3 in liver; and nonsynonymous SNPs rs1716975 and rs2272007 in ULK4, which are associated with altered expression of ULK4 in lymphoblastoid cell lines. In addition, rs7571613 near PMS1 and MSTN is associated with altered expression of ORMDL1 and PMS1 in lymphoblastoid cell lines. Additional eSNPs with suggestive evidence of association with blood pressure phenotypes were rs7537765 near MTHFR-NPPA (expressed gene CLCN6), and several SNPs in KDM5A that are associated with expression of KDM5A, SLC6A12 and CCDC77.
DISCUSSION
In this meta-analysis of results from 29,136 participants from six large prospective observational studies in the CHARGE Consortium, we identified multiple loci with evidence of association with levels of systolic and diastolic blood pressure and hypertension. We further replicated genome-wide significant SNPs in 34,433 independent subjects from the Global BPgen Consortium, and the joint analysis of results from the two consortia identified 11 genome-wide significant associations: four loci for SBP (ATP2B1, P ¼ 3.8 Â 10 À11 ; CYP17A1, P ¼ 1.3 Â 10 À10 ; PLEKHA7, P ¼ 1.9 Â 10 À9 ; SH2B3, P ¼ 4.5 Â 10 À9 ), six loci for DBP (ATP2B1, P ¼ 1.5 Â 10 À9 ; CACNB2, P ¼ 1.2 Â 10 À8 ; MAF, minor allele frequency. Beta is the effect size on blood pressure in mm Hg, per allele based on the additive genetic model.
) and one locus for hypertension (ATP2B1, P ¼ 1.8 Â 10 À11 ). There was considerable concordance among top loci across all three phenotypes: ATP2B1 showed significant association with SBP, DBP and hypertension, CACNB2 showed strong evidence of association with all three traits and SH2B3 showed significant association with SBP and DBP. Of note, rs1004467, a common intronic variant in CYP17A1, a gene associated with a rare mendelian form of hypertension, emerged as a genomewide significant locus in the meta-analysis of results from both consortia. Several additional loci showed suggestive association results, including MDS1, ITGA9, EDN3 and PMS1-MSTN. The top ten risk alleles for SBP and DBP within CHARGE were each associated with about a 1 and 0.5 mm Hg increase in SBP and DBP, respectively; there was a continuous and graded relation of the number of risk alleles to mean levels of SBP and DBP and odds ratios for hypertension. Last, analysis of gene expression associated SNPs within our GWAS provided additional promising blood pressure candidates (by virtue of the identified expressed genes), including KDM5A-SLC6A12-CCDC77, ORMDL1 and CLCN6. We identified genome-wide significant association of ATP2B1 with SBP, DBP and hypertension (17% increase in odds per risk allele and 37% increase for two risk alleles). This gene encodes PMCA1, a plasma membrane calcium/calmodulin-dependent ATPase that is expressed in vascular endothelium and is involved in calcium pumping from the cytosol to the extracellular compartment 24 . An investigation of cultured rat aortic smooth muscle cells found elevated PMCA1 mRNA levels in spontaneously hypertensive rats compared to nonhypertensive controls, consistent with a role of ATP2B1 in blood pressure regulation 25 .
Genetic variation can contribute to altered blood pressure regulation by altering the structure of encoded proteins or by altering gene expression (that is, protein quantity). For SH2B3 we have strong evidence to support both mechanisms; a missense SNP (altered protein structure) and an eSNP (altered expression) were associated with blood pressure. Our most highly significant SNP for DBP (and our second strongest signal for SBP) was the nonsynonymous SNP rs3184504 in SH2B3 ( Tables 1, 2 and 4), which introduces the aminoacid substitution W262R in a plekstrin homology domain on exon 3. This coding variant is predicted by PolyPhen 26 to be probably damaging to the encoded protein. This SNP has recently also been found to be reproducibly associated with type 1 diabetes mellitus and celiac disease 27, 28 . The association of this SNP with two autoimmune diseases suggests that immune response pathways may influence blood pressure by mechanisms previously not appreciated. SH2B3 knockout mice are viable but show increased sensitivity to cytokines and abnormal growth factor signaling 29 . In addition, eSNP rs739496 ( Table 5 ) was associated with blood pressure levels and with liver expression of a transcript adjacent to SH2B3. SH2B3 is located in a large block of linkage disequilibrium on chromosome 12 that contained multiple association signals across 700 kb from rs3184504 in SH2B3 to rs11066188 in C12orf51 for SBP and DBP, and that contains many genes (Fig. 1, Fig. 2 and Supplementary Fig. 2 ). Located near the midpoint between SH2B3 and C12orf51 is ALDH2, encoding acetaldehyde dehydrogenase 2, a critical enzyme in alcohol metabolism. A recent meta-analysis found that male homozygotes for the K671E variant (rs671) in ALDH2 had an increased odds of hypertension (odds ratio 2.42, P ¼ 4.8 Â 10 À6 ) and 7 mm Hg higher mean SBP (P ¼ 1.1 Â 10 À12 ) when compared with major allele homozygotes 30 . Although rs671 is absent in individuals of European descent in HapMap and was not included in our GWAS, our intriguing findings in the region encircling ALDH2 are consistent with a role of this gene in blood pressure regulation in people of European descent.
Another SNP (rs1004467) attaining genome-wide significance is in CYP17A1, encoding steroid 17-alpha-hydroxylase, an enzyme necessary for steroidogenesis. Mutations in CYP17A1 are found in individuals with 17a-hydroxylase deficiency, which is characterized by congenital adrenal hyperplasia with apparent mineralocorticoid excess, salt retention, hypokalemia and hypertension 31 ; these mutations can lead to a spectrum of phenotypic severity 32 . Although mutations in CYP17A1 causing phenotypic 17a-hydroxylase deficiency are rare, our data suggest that common variants in CYP17A1 may also be associated with blood pressure by promoting mild forms of enzyme deficiency or dysfunction.
CACNB2, encoding the beta-2 subunit of a voltage-gated calcium channel, was associated with DBP and showed suggestive evidence of association with SBP and hypertension. The gene is expressed in the heart and a nonsynomymous variant in CACNB2 was identified in affected individuals with Brugada syndrome 33 . CACNB2 is one member of a family of voltage-gated calcium channel genes, several of which have effects on blood pressure regulation and serve as targets of calcium channel blockers. The beta-2 subunit interacts with alpha-1 calcium channels (Ca V 1.2) and this is a mechanism by which variation in CACNB2 may alter blood pressure 34 .
The joint meta-analysis of CHARGE and Global BPgen ( Table 4 ) also identified PLEKHA7, ULK4, TBX3-TBX5 and a region adjacent to CSK-ULK3-CYP1A2 as genome-wide significant loci. Mutations in TBX5 (T-box transcription factor 5) cause structural cardiac malformations and can be associated with altered expression of NPPA 35 , which also was a locus of interest in our eSNP analysis. CSK encodes cytoplasmic tyrosine kinase, which is involved in angiotensin IIdependent vascular smooth muscle cell proliferation 36 . Little is known about ULK3 or ULK4 and how variation in these genes might affect blood pressure. Three CHARGE loci that were identified as genome-wide significant in this analysis were also found to be genome-wide significant in the Global BPgen Consortium metaanalysis: CYP17A1 (rs1004467 in CYP17A1 in CHARGE versus rs11191548 in Global BPgen, respectively; r 2 ¼ 0.42), SH2B3-ATXN2 (rs3184504 versus rs653178; r 2 ¼ 1.0), and a locus containing CSK-ULK3-CYP1A2 (rs6495122 versus rs4886606; r 2 ¼ 0.56). In addition, both consortia identified MDS1 as a locus of interest (rs448378 versus rs1918974; r 2 ¼ 1.0). The region containing MTHFR-NPPA, which attained genome-wide significance in Global BPgen, was identified as a region of interest in the CHARGE analysis of eSNPs (Table 5 ; rs7537765 in CHARGE vs. rs17367504 in Global BPgen; r 2 ¼ 0.94). Other loci of interest (5 Â 10 À8 o P o 4 Â 10 À7 ) in the joint analysis of CHARGE and Global BPgen were MDS1 (rs448378, P ¼ 1.2 Â 10 À7 ) and a region adjacent to EDN3 (rs16982520, P ¼ 1.6 Â 10 À7 ). Endothelin-3 may have a role in renal-mediated hypertension in the rat 37 . A search for putative functional variation within our GWAS identified five nonsynonymous SNPs. In addition to rs3184504 in SH2B3 (discussed above), rs267561 in ITGA9, which showed suggestive evidence of association with hypertension (P ¼ 2.6 Â 10 À6 ), produces an E507G substitution that is predicted by PolyPhen to have possibly damaging effects 26 . Three linked nonsynonymous SNPs in ULK4 showed suggestive evidence of association with DBP (rs2272007, P ¼ 1.5 Â 10 -6 ; rs3774372, P ¼ 1.6 Â 10 À6 ; rs1716975, P ¼ 2.2 Â 10 À6 ; pairwise r 2 ¼ 0.82-1.0); these amino-acid substitutions are predicted to be benign individually, but their conjoint effects on protein function is unknown. Interrogation of our GWAS results for SNPs that are associated with blood pressure phenotypes and altered gene expression confirmed SH2B3, ULK4 and ULK3 as loci of interest ( Table 5) .
Another locus detected via eSNP associations with blood pressure was rs7537765 near NPPA, which encodes atrial natriuretic peptide and which was in linkage disequilibrium with rs198358 (r 2 ¼ 0.58), a SNP that has been shown to be associated with higher circulating natriuretic peptide levels and lower SBP 38 . Other promising candidates by virtue of the expressed genes in our eSNP analysis are KDM5A-SLC6A12-CCDC77, ORMDL1-PMS1 and CLCN6.
Although the conjoint effect of multiple risk alleles on blood pressure can be substantial, our findings underscore the small effect size of individual common allelic variants-about 1 mm Hg each for systolic and 0.5 mm Hg each for diastolic blood pressure per variant alleleand the necessity of very large sample sizes for detection of robust and significant results. The combined analysis of CHARGE and Global BPgen for our top SNPs reflects a sample size of 63,569 individuals and illustrates the advantage of large consortia for meta-analysis of Boldface P values are o1/n, where n is the number of eSNPs interrogated.
a P value for association of eSNP with gene expression in liver or lymphoblastoid cell lines. genome-wide data to identify new clues about the genetic underpinnings of common complex traits. Given the small effect sizes detected, it is not surprising that previous blood pressure GWAS failed to identify genome-wide significant results at P o 5 Â 10 À8 (refs. [13] [14] [15] [16] [17] [18] . Understanding of allelic variation affecting blood pressure in the general population is in its infancy; until recently, there were few known genetic variants reproducibly associated with blood pressure variation. Our CHARGE findings, in conjunction with those of the Global BPgen Consortium 20 , establish the utility of genome-wide association approaches to identify common allelic variants pertaining to blood pressure physiology and pathophysiology. Our findings are consistent with the hypothesis that variation in scores, if not hundreds, of genes contribute to blood pressure variation. This hypothesis is supported by the excess number of SNPs showing association at P o 1 Â 10 À3 with blood pressure phenotypes. Future efforts to identify additional alleles associated with blood pressure will require complementary strategies, including larger genome-wide studies to identify additional common alleles and resequencing efforts in large samples to identify rare variants.
In aggregate, the proportion of blood pressure variation explained by the top ten CHARGE SBP-and DBP-associated SNPs across the six cohorts is 1% (increment in r 2 ) after accounting for the major nongenetic determinants of blood pressure: age, age squared, sex and body mass index. The conjoint effect of multiple risk alleles on blood pressure levels, however, amounts to several mm Hg (Fig. 3) , which is sufficient to increase cardiovascular disease risk. Observational data indicate that a prolonged increase in DBP of 5 mm Hg is associated with a 34% increase in risk for stroke and a 21% increase in risk of coronary events 39 .
Future analyses using larger samples can benefit from specific features of our study design. First, the vast majority of blood pressure values used in our analyses were obtained more than 15 years ago, when blood pressure treatment, which confounds genetic analyses, was less widely used; contemporary blood pressure data might be less likely to reveal genetic associations. Second, because allelic variation may affect both the low and high ends of the blood pressure distribution, we used the more powerful approach of analyzing blood pressure as a continuous trait, yet we also identified a genome-wide significant locus for hypertension. At the same time, one should recognize that our study results, based on participants of European descent, cannot necessarily be generalized to other populations. Although our analysis of eSNPs indicates that some of the genome-wide significant blood pressure loci we identified are associated with altered gene expression, the relevance of these findings to blood pressure is speculative. A similar approach, however, has been used to identify putative disease genes for childhood asthma 40 , Crohn's disease 41 and a network of genes implicated in obesity 42 .
In conclusion, we have identified multiple genome-wide significant blood pressure loci that can be used to guide fine-mapping efforts to pinpoint causal variants and to understand how the implicated genes alter blood pressure physiology and contribute to hypertension. The characterization of new blood pressure-associated loci can serve as a basis for future approaches to early detection of high-risk individuals and for the development of novel therapies for the prevention or treatment of hypertension.
METHODS
Consortium organization. The CHARGE Consortium 19 includes six cohort studies that completed genome-wide genotyping and had extensive data on multiple phenotypes including blood pressure. Each study adopted collaboration guidelines and established a consensus on phenotype harmonization, covariate selection and an analytical plan for within-study genome-wide association and prospective meta-analysis of results across studies. Each study received institutional review board approval of its consent procedures, examination and surveillance components, data security measures, and DNA collection and its use for genetic research. All participants in each study gave written informed consent for participation in the study and the conduct of genetic research. Details of each study, blood pressure measurement protocols, inclusion and exclusion criteria, and genotyping are provided in the Supplementary Methods and Supplementary Tables 1 and 3 online.
Genotype imputation. For imputation of genotypes to the HapMap set of approximately 2.5 million SNPs, ARIC, FHS and RS used a hidden Markov model as implemented in MACH 43 , and CHS used BIMBAM10 v0.99 (ref. 44 and Supplementary Table 3) . SNP imputation combined genotype data from each sample with the HapMap CEU samples and then inferred genotypes probabilistically according to shared haplotype stretches between study samples and HapMap release 22 build 36. Imputation results are summarized as an 'allele dosage' defined as the expected number of copies of the minor allele at that SNP (a fractional value between 0.0 and 2.0) for each genotype.
Statistical analyses. Cross-sectional analyses were conducted within each cohort using an additive genetic model, and within-study associations were combined by prospective meta-analysis. The phenotypes for meta-analysis were systolic and diastolic blood pressure and hypertension at the first examination attended. For participants who were taking antihypertensive medication we added 10 mm Hg to observed SBP values and 5 mm Hg to DBP values 45 . Hypertension was defined as SBP Z 140 or DBP Z 90 mm Hg or drug treatment for hypertension at time of assessment. Within each cohort, regression models were fitted for systolic and diastolic blood pressure (separately) and allele dosage, adjusting for sex, age, age squared and BMI.
Meta-analysis of results was carried out using inverse-variance weighting. Before meta-analysis, results were filtered for minor allele frequency o0.005 and the genomic control parameter was calculated to adjust each study. After meta-analysis, the genomic control parameter was recalculated to adjust for between-study heterogeneity 46 . A predetermined threshold of 4 Â 10 À7 (stage 1) was used to indicate genome-wide significance within CHARGE. For 2.5 Â 10 6 tests (the total number of imputed SNPs), this threshold means that the expected number of false-positive results is r1; the validity of this bound is not affected by correlation between test statistics 47 .
Ten leading SNPs for SBP, ten for DBP and ten for hypertension were exchanged between CHARGE and Global BPgen, a consortium with a sample size of 34,433 individuals of European ancestry with analogous genome-wide data 38 . SNP selection was limited to one SNP per locus of interest, defined by an r 2 r 0.2. For rs880315, imputation in Global BPgen was suboptimal and this SNP was replaced with rs12046272. rs8096897 and rs10972206 were not selected for exchange owing to low minor allele frequencies (defined as o0.01 for continuous traits, o0.05 for hypertension). rs5761405 was selected for exchange, but was not available in the imputed results from Global BPgen, so the next most highly significant locus was selected in its place. For all 30 exchanged SNPs we carried out meta-analysis of CHARGE and Global BPgen results using inversevariance weighting and considered a P value in the joint analysis (stage 2) significant at P ¼ 5 Â 10 À8 . Significant replication of a genome-wide significant SNP in CHARGE was defined as a P value o0.008 for the same SNP in Global BPgen (0.05/6 genome-wide significant SNPs submitted for replication). Onesided tests were used to assess replication when the alignment of an allele and its directional effect were identical between CHARGE and Global BPgen.
Analysis of hypertension was conducted within each cohort, and the withinstudy associations were combined by meta-analysis. Within each cohort, regression models were fitted for hypertension, adjusting for sex, age, age squared and BMI. Meta-analysis of results was carried out using inversevariance weighting. Before meta-analysis, results were filtered for low minor allele frequency o0.01 and the genomic control parameter calculated to adjust each study. After meta-analysis, the genomic control parameter was calculated again to adjust for between-study heterogeneity. In the meta-analysis of CHARGE and Global BPgen, the analytical approach used in Global BPgen was different from that of CHARGE; in Global BPgen nonhypertensive controls were defined as individuals not taking any hypertensive medications and having a SBP r 120 mm Hg and a DBP r 85 mm Hg.
Blood pressure risk score was a weighted sum across ten top SNPs (separately for systolic and diastolic blood pressure) combining beta coefficients and doses of risk alleles, rounded to 1 mm Hg for SBP (groups r6 to Z15) and 0.5 mm Hg for diastolic blood pressure (groups r2.5 to Z7.5). Within a study, for each risk score group we calculated deviations of empirical blood pressure from the study mean. Across studies, we estimated mean deviation and standard error within risk score group, weighted by groupand study-specific sample sizes. For hypertension, odds ratios (and standard errors) were the corresponding summary statistics, with the reference group being those with a weighted systolic risk score of 10 or a diastolic score of 5.
SNP associations with altered gene expression. To assess putative functional associations in our GWAS, we used bioinformatics tools to query existing GWAS databases of SNPs associated with cis-gene expression levels in immortalized liver (n ¼ 3,322) 22 and lymphoblastoid cell lines (n ¼ 10,823) 23 . These expression-associated SNPs were then explored for association with blood pressure in the fully imputed HapMap blood pressure results for CHARGE. Statistical significance was defined by a P value of 1/n (where n is the number of tissue-specific cis eSNPs interrogated); this threshold will yield on average one false positive per tissue examined. The P-value thresholds for significance of eSNP associations for liver and lymphoblastoid cell lines were 3.0 Â 10 À4 and 9.2 Â 10 À5 , respectively.
Note: Supplementary information is available on the Nature Genetics website.
